Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.

Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA.

Cancer Res. 2019 Jul 30. pii: canres.0698.2019. doi: 10.1158/0008-5472.CAN-19-0698. [Epub ahead of print]

PMID:
31362929
2.

Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model.

Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

FEBS Open Bio. 2019 Jul 17. doi: 10.1002/2211-5463.12702. [Epub ahead of print]

3.

Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer.

Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T.

Oncotarget. 2019 Jan 25;10(8):810-824. doi: 10.18632/oncotarget.26574. eCollection 2019 Jan 25.

4.

Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker.

Pérez-Morales J, Mejías-Morales D, Rivera-Rivera S, González-Flores J, González-Loperena M, Cordero-Báez FY, Pedreira-García WM, Chardón-Colón C, Cabán-Rivera J, Cress WD, Gordian ER, Muñoz-Antonia T, Cabrera-Ríos M, Isidro A, Coppola D, Rosa M, Boyle TA, Izumi V, Koomen JM, Santiago-Cardona PG.

PLoS One. 2018 Nov 19;13(11):e0207483. doi: 10.1371/journal.pone.0207483. eCollection 2018.

5.

A double recombinant herpes virus of turkeys for the protection of chickens against Newcastle, infectious laryngotracheitis and Marek's diseases.

Gergen L, Cook S, Ledesma B, Cress W, Higuchi D, Counts D, Cruz-Coy J, Crouch C, Davis P, Tarpey I, Morsey M.

Avian Pathol. 2019 Feb;48(1):45-56. doi: 10.1080/03079457.2018.1546376. Epub 2018 Nov 30.

PMID:
30404540
6.

Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.

Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiappori AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, Yabar-Berrocal A, Motta-Guerrero R, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

J Thorac Oncol. 2017 Dec;12(12):1851-1856. doi: 10.1016/j.jtho.2017.08.019. Epub 2017 Sep 11.

7.

Evaluating somatic tumor mutation detection without matched normal samples.

Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, Berglund AE.

Hum Genomics. 2017 Sep 4;11(1):22. doi: 10.1186/s40246-017-0118-2.

8.

Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.

Cress WD, Yu P, Wu J.

Int J Biochem Cell Biol. 2017 Oct;91(Pt B):98-101. doi: 10.1016/j.biocel.2017.05.013. Epub 2017 May 11. Review.

9.

A stitch in time and CDK9.

Cress WD.

Cell Cycle. 2017 May 3;16(9):823-824. doi: 10.1080/15384101.2017.1308150. Epub 2017 Mar 16. No abstract available.

10.

Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.

He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22842. No abstract available.

11.

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.

Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD.

Oncotarget. 2016 Dec 13;7(50):82254-82265. doi: 10.18632/oncotarget.12672.

12.

Strategies for power calculations in predictive biomarker studies in survival data.

Chen DT, Huang PY, Lin HY, Haura EB, Antonia SJ, Cress WD, Gray JE.

Oncotarget. 2016 Dec 6;7(49):80373-80381. doi: 10.18632/oncotarget.12124.

13.

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN.

Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.

14.

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.

Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L.

J Clin Invest. 2016 Jun 1;126(6):2267-79. doi: 10.1172/JCI85250. Epub 2016 May 3.

15.

A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.

Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD.

J Thorac Oncol. 2016 Jun;11(6):838-49. doi: 10.1016/j.jtho.2016.02.009. Epub 2016 Feb 23.

16.

The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts.

Sosa-García B, Vázquez-Rivera V, González-Flores JN, Engel BE, Cress WD, Santiago-Cardona PG.

PLoS One. 2015 Nov 10;10(11):e0142406. doi: 10.1371/journal.pone.0142406. eCollection 2015.

17.

Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma.

Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cai J, Cress WD, Wu J.

Br J Cancer. 2015 Dec 22;113(12):1735-43. doi: 10.1038/bjc.2015.378. Epub 2015 Nov 10.

18.

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.

Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA.

Oncogene. 2016 Jun 16;35(24):3209-16. doi: 10.1038/onc.2015.375. Epub 2015 Oct 19.

19.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

20.

Lung cancer mutations and use of targeted agents in Hispanics.

Cress WD, Chiappori A, Santiago P, Muñoz-Antonia T.

Rev Recent Clin Trials. 2014;9(4):225-32. Review.

21.

THE RETINOBLASTOMA PROTEIN: A MASTER TUMOR SUPPRESSOR ACTS AS A LINK BETWEEN CELL CYCLE AND CELL ADHESION.

Engel BE, Cress WD, Santiago-Cardona PG.

Cell Health Cytoskelet. 2015;7:1-10. doi: 10.2147/CHC.S28079. Epub 2014 Dec 18.

22.

Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.

Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ.

J Natl Cancer Inst. 2014 Dec 1;107(1):358. doi: 10.1093/jnci/dju358. Print 2015 Jan.

23.

Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines.

Chen L, Muñoz-Antonia T, Cress WD.

PLoS One. 2014 Jul 1;9(7):e101040. doi: 10.1371/journal.pone.0101040. eCollection 2014.

24.

E2F inhibition synergizes with paclitaxel in lung cancer cell lines.

Kurtyka CA, Chen L, Cress WD.

PLoS One. 2014 May 15;9(5):e96357. doi: 10.1371/journal.pone.0096357. eCollection 2014.

25.

TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4203-8. doi: 10.1073/pnas.1319269111. Epub 2014 Feb 28.

26.

Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors.

Engel BE, Welsh E, Emmons MF, Santiago-Cardona PG, Cress WD.

Cell Death Dis. 2013 Nov 28;4:e938. doi: 10.1038/cddis.2013.461.

27.

Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.

Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD.

J Biol Chem. 2012 Nov 23;287(48):40106-18. doi: 10.1074/jbc.M112.380865. Epub 2012 Oct 11.

28.

Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.

Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD.

J Natl Cancer Inst. 2011 Dec 21;103(24):1859-70. doi: 10.1093/jnci/djr420. Epub 2011 Dec 8.

29.

Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer.

Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD.

PLoS One. 2011;6(10):e24923. doi: 10.1371/journal.pone.0024923. Epub 2011 Oct 27.

30.

E2F1: A new role in the DNA damage response.

Cress WD.

Cell Cycle. 2011 Jun 1;10(11):1718. Epub 2011 Jun 1. No abstract available.

31.

CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.

Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M.

J Clin Invest. 2011 Apr;121(4):1549-60. doi: 10.1172/JCI44539. Epub 2011 Mar 14.

32.

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.

Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S.

PLoS One. 2010 Dec 14;5(12):e14335. doi: 10.1371/journal.pone.0014335.

33.

A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation.

Sosa-García B, Gunduz V, Vázquez-Rivera V, Cress WD, Wright G, Bian H, Hinds PW, Santiago-Cardona PG.

PLoS One. 2010 Nov 11;5(11):e13954. doi: 10.1371/journal.pone.0013954.

34.

RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor.

Freeman SN, Cress WD.

Cancer Biol Ther. 2010 Dec 1;10(11):1123-5. Epub 2010 Dec 1. No abstract available.

PMID:
20980811
35.

CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD.

J Biol Chem. 2010 Mar 26;285(13):9813-22. doi: 10.1074/jbc.M109.091496. Epub 2010 Jan 27.

36.

A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.

Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, Barrett A, Aslanidi G, Cress WD, Law B.

J Biol Chem. 2009 Oct 23;284(43):29945-55. doi: 10.1074/jbc.M109.055251. Epub 2009 Aug 26.

37.

Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.

He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ.

J Biol Chem. 2008 Nov 7;283(45):31012-20. doi: 10.1074/jbc.M803547200. Epub 2008 Sep 7. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22842.

38.

A small-molecule E2F inhibitor blocks growth in a melanoma culture model.

Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W, Cress WD.

Cancer Res. 2008 Aug 1;68(15):6292-9. doi: 10.1158/0008-5472.CAN-08-0121.

39.

Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells.

Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H.

Mol Cancer Res. 2008 Jul;6(7):1099-105. doi: 10.1158/1541-7786.MCR-07-2177.

40.

RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis.

Freeman SN, Ma Y, Cress WD.

J Biol Chem. 2008 Jan 25;283(4):2353-62. Epub 2007 Nov 26.

41.

Regulation of E2F1 function by the nuclear corepressor KAP1.

Wang C, Rauscher FJ 3rd, Cress WD, Chen J.

J Biol Chem. 2007 Oct 12;282(41):29902-9. Epub 2007 Aug 17.

43.

Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.

Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD, Chen J.

Nat Cell Biol. 2006 Sep;8(9):1025-31. Epub 2006 Aug 6.

PMID:
16892051
44.

Bok, Bcl-2-related Ovarian Killer, Is Cell Cycle-regulated and Sensitizes to Stress-induced Apoptosis.

Rodriguez JM, Glozak MA, Ma Y, Cress WD.

J Biol Chem. 2006 Aug 11;281(32):22729-35. Epub 2006 Jun 13.

45.

E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts.

Frame FM, Rogoff HA, Pickering MT, Cress WD, Kowalik TF.

Oncogene. 2006 Jun 1;25(23):3258-66. Epub 2006 Jan 23.

PMID:
16434972
46.

Role of Stat3 in regulating p53 expression and function.

Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H.

Mol Cell Biol. 2005 Sep;25(17):7432-40.

47.

Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

Freeman SN, Bepler G, Haura E, Sutphen R, Cress WD.

J Natl Cancer Inst. 2005 Jul 20;97(14):1088-9; author reply 1093-5. No abstract available.

PMID:
16030308
48.

Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism.

Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, Chen J.

J Biol Chem. 2005 Apr 1;280(13):12339-43. Epub 2005 Feb 14.

49.

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.

Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E.

Lung Cancer. 2005 Feb;47(2):183-92.

PMID:
15639717
50.

E2F4 deficiency promotes drug-induced apoptosis.

Ma Y, Freeman SN, Cress WD.

Cancer Biol Ther. 2004 Dec;3(12):1262-9. Epub 2004 Dec 14.

PMID:
15611646

Supplemental Content

Support Center